If you snore loudly, wake up feeling tired after a full night's sleep, or your partner has noticed you stop breathing during the night, you may have obstructive sleep apnea. And if you are also taking a GLP-1 medication like Wegovy, Ozempic or Mounjaro, there is very good news: these medications may be benefiting your health in ways you haven't even noticed — including for your breathing at night.

This article explains what sleep apnea is, what the research shows about GLP-1 medications and sleep apnea, and what this means practically for your treatment.

What is obstructive sleep apnea?

Obstructive sleep apnea (OSA) is a condition where the muscles of the throat relax and block the airway repeatedly during sleep, causing brief pauses in breathing. These pauses — called apneas — can happen dozens or even hundreds of times per night. Each time, the brain detects falling oxygen levels and briefly rouses you to resume breathing, often without you remembering it in the morning.

The consequences are significant. Poor sleep quality leads to daytime fatigue, difficulty concentrating, irritability and impaired memory. Over the long term, untreated sleep apnea raises the risk of high blood pressure, heart disease, stroke and type 2 diabetes.

OSA is very common — and very underdiagnosed. It is estimated that up to 80% of cases in adults remain undetected. Weight is one of the strongest risk factors: fat tissue around the neck and upper airway narrows the breathing passage, and excess abdominal weight pushes up against the diaphragm when lying down. Studies show that a 10% increase in body weight is associated with a sixfold increase in the risk of moderate-to-severe sleep apnea.

What does the research show about GLP-1 and sleep apnea?

The evidence is striking. In the SURMOUNT-OSA trial, published in the New England Journal of Medicine in 2024, adults with obesity and moderate-to-severe obstructive sleep apnea were treated with tirzepatide (Mounjaro) for 52 weeks. The results:

These results were so compelling that in June 2024, the FDA approved tirzepatide (under the brand name Zepbound) specifically for treating moderate-to-severe obstructive sleep apnea in adults with obesity — the first approval of a medication for this indication in the obesity-OSA patient group.

Semaglutide (Wegovy/Ozempic) has also shown benefits for OSA through its weight-loss effects, though its specific approval is for obesity and type 2 diabetes management, not sleep apnea.

How does weight loss improve sleep apnea?

The primary mechanism is straightforward: losing weight reduces the fat tissue around the neck, throat and upper airway. A thinner airway lining means the passage stays more open during sleep. Reduced abdominal fat also decreases pressure on the diaphragm, making it easier to breathe when lying down.

There may also be a direct effect of GLP-1 receptors in the brain on breathing regulation, and some research suggests that tirzepatide's benefits for OSA exceed what weight loss alone would predict. This is an area of ongoing investigation.

Should you stop using CPAP if you start GLP-1 medication?

No — not without speaking to your doctor first. CPAP (continuous positive airway pressure) therapy remains the gold standard for treating moderate-to-severe OSA and should never be discontinued without medical supervision and a reassessment.

However, if you lose significant weight with GLP-1 medication, it is entirely reasonable to discuss with your doctor whether a follow-up sleep study is warranted. Your CPAP pressure settings may need adjusting as your airway changes, and in some cases — particularly after substantial weight loss — some people find that their sleep apnea has resolved or improved enough that CPAP is no longer needed. Your doctor can arrange a repeat polysomnography (sleep study) to assess your current OSA severity.

How do I know if I have sleep apnea?

The most common signs of OSA are:

If you have several of these symptoms — especially if you have overweight, obesity or a thick neck — speak to your doctor about the possibility of a sleep study. Diagnosis is made through a home sleep test or a full overnight polysomnography in a sleep clinic.

What can you do while waiting for a diagnosis or treatment?

While you wait for a sleep study or are managing existing OSA, several steps can help:

The bigger picture: sleep apnea and overall health

For many people taking GLP-1 medication for weight management, sleep apnea may be a significant — and undiagnosed — contributor to fatigue, cardiovascular risk and metabolic dysfunction. The benefits of treating both obesity and OSA simultaneously are substantial. Improved sleep quality can itself support weight management: better sleep improves insulin sensitivity, reduces cravings, lowers cortisol and increases the energy available for physical activity.

The approval of tirzepatide for sleep apnea also signals an important shift in how OSA is being treated. Traditionally, management focused on CPAP devices and positional therapy. A pharmacological treatment that addresses a root cause — excess weight — represents a meaningful advance for the millions of people who struggle to tolerate CPAP long-term.

Conclusion

GLP-1 medications offer a remarkable dual benefit for people with obesity and sleep apnea: significant weight loss that directly reduces OSA severity, and — for tirzepatide specifically — an FDA-approved indication for treating moderate-to-severe sleep apnea. If you suspect you may have sleep apnea, or if you have been diagnosed and are now taking a GLP-1 medication, it is worth discussing your sleep health with your doctor. Better nights may be closer than you think.

Always speak to your doctor before making any changes to your treatment. Do not stop using CPAP therapy without medical supervision.

Sources